In vitro studies targeting BRAFV600E‐mutant CRC suggest that SHP2 inhibitors (TNO155) can enhance the ability of BRAF and MEK inhibitors to kill tumour cells134 (Table 2). Here, MAP2K7 is linked to colorectal carcinoma.